15/03/23 -"FY22 broadly in-line with expectations – 2023 guidance of yoy flat EBITDA offers slight upward revision potential and underpins LXS’ defensiveness"
15/03/23 -"FY22 broadly in-line with expectations – 2023 guidance of yoy flat EBITDA offers slight upward revision potential and underpins LXS’ defensiveness"
AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.
| Corporate broking | NO |
| Trading in corporate shares | NO |
| Analyst ownership | NO |
| Advising of corporate (strategy, marketing, debt, etc) | NO |
| Research paid for by corporate | NO |
| Provision of corporate access paid for by corporate | NO |
| Link between and a banking entity | NO |
| Brokerage activity at AlphaValue | NO |